Consortium of Swiss Academic Libraries

GAP-independent functions of DLC1 in metastasis

Barras, David ; Widmann, Christian

In: Cancer and Metastasis Reviews, 2014, vol. 33, no. 1, p. 87-100

Université de Fribourg

Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer

Lan, Qiang ; Peyvandi, Sanam ; Duffey, Nathalie ; Huang, Yu-Ting ; Barras, David ; Held, Werner ; Richard, François ; Delorenzi, Mauro ; Sotiriou, Christos ; Desmedt, Christine ; Lorusso, Girieca ; Rüegg, Curzio

In: Oncogene, 2019, vol. 38, no. 15, p. 2814–2829

Neoadjuvant and adjuvant chemotherapies provide survival benefits to breast cancer patients, in particular in estrogen receptor negative (ER−) cancers, by reducing rates of recurrences. It is assumed that the benefits of (neo)adjuvant chemotherapy are due to the killing of disseminated, residual cancer cells, however, there is no formal evidence for it. Here, we provide experimental...

Université de Fribourg

Fragment N2, a caspase-3-generated RasGAP fragment, inhibits breast cancer metastatic progression

Barras, David ; Lorusso, Girieca ; Lhermitte, Benoît ; Viertl, David ; Rüegg, Curzio ; Widmann, Christian

In: International Journal of Cancer, 2014, p. -

The p120 RasGAP protein negatively regulates Ras via its GAP domain. RasGAP carries several other domains that modulate several signaling molecules such as Rho. RasGAP is also a caspase-3 substrate. One of the caspase-3-generated RasGAP fragments, corresponding to amino acids 158–455 and called fragment N2, was previously reported to specifically sensitize cancer cells to death induced by...